Virtu Financial LLC Salarius Pharmaceuticals, Inc. Transaction History

Virtu Financial LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$0.16 - $0.42 $6,831 - $17,931	42,694 Added 108.15%	82,170 $17,000
Q1 2022 May 17, 2022	BUY	$0.34 - $0.54 $13,421 - $21,317	39,476 New	39,476 $16,000
Q4 2021 Feb 17, 2022	SELL	$0.49 - $1.01 $14,556 - $30,005	-29,708 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$0.8 - $1.15 $23,766 - $34,164	29,708 New	29,708 $30,000
Q2 2021 Sep 17, 2021	SELL	$1.02 - $1.52 $13,748 - $20,488	-13,479 Closed	0 $0

Q1 2021 May 19, 2021	BUY	$1.0 - $3.0 $13,479 - $40,437	13,479 New	13,479 $20,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $5.43M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.